US-China Economic and Trade Agreement Phase 1 – Pharmaceutical related IP issues
Richard Glanton, Chairman of Board of directors of UCIPF
Overview of IP provisions of the recent Economic and Trade Agreement between U.S. and China phase 1
Mark Cohen, Lecturer in Law, Distinguished Senior Fellow, and Director at the University of California at Berkeley
Advisory Board, UCIPF
Supplemental Data filing in China and Patent Term Extension
- Current practice for post filing data in China
Luke Zuo, Senior Partner, NTD Patent & Trademark Agency Limited
- Current challenges for US Pharmaceutical companies for posting filing data issues in China
R. Craig Tucker, Senior Patent Counsel, Eli Lilly
- What we expect that China implement the IP provisions of the Economic and Trade Agreement in the future for Post filing data
- Patent Term Extension
Tom Hoxie, Managing Partner, Hoxie & Associates LLC.
Demi Wang, Founder, Chief Executive Officer
Thank you to our supporters!
Richard H. Glanton
Larry (Lubing) Lian
Luke Zuo, M.D.
R. Craig Tucker
Demi Wang – Founder, Chief Executive Officer